US FDA Balances Urgent Need For Platinum Chemotherapies Against Intas Plant’s Quality Failures

As politicians demand help for cancer-ridden constituents, the agency allows Indian plant that flunked inspection to resume exporting batches of cisplatin and carboplatin to the US, but only after passing independent 45-day batch certification reviews.